Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children

Giorgio Radetti, Gianluca D’Addato, Davide Gatti, Mauro Bozzola and Silvano Adami

Department of Paediatrics, Regional Hospital of Bolzano, via L. Boehler 5, 39100 Bolzano, Italy, Department of Paediatrics, University of Pavia, Pavia, Italy and Rheumatologic Department, Hospital of Valeggio (VR), Verona, Italy

(Correspondence should be addressed to G. Radetti; Email: giorgio.radetti@asbz.it)

Abstract

Objective: The aim was to investigate the effects of two different GH dosage regimens on growth, bone geometry and bone strength.

Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SDS, the inner and outer diameters; and the total cross-sectional area (CSA), cortical CSA, medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children, treated with two different doses of GH. Group 1 (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week.

Results: At the end of treatment, with group 1 vs group 2, height SDS was 2.0.84 ± 1.07 vs 2.0.46 ± 0.76, and parentally adjusted height SDS was 0.14 ± 1.08 vs 0.27 ± 0.82. Parentally adjusted relative height gain was 1.14 ± 0.89 vs 2.14 ± 0.72 SDS (P = 0.0001). MI SDS was 0.58 ± 1.31 vs 0.42 ± 1.54 (P < 0.005). MI SDS gain was 0.07 ± 1.41 vs 0.35 ± 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P = 0.05). BBRI was 10.02 ± 5.37 vs 11.52 ± 5.49 cm³, and BBRI gain was 3.33 ± 5.06 vs 6.88 ± 6.65 (P = 0.01). P values were assessed using student’s t-test.

Conclusion: Higher GH doses result in a greater height gain and improved bone strength.

European Journal of Endocrinology 154 479–482

Introduction

Growth hormone (GH) promotes longitudinal growth by stimulating the epiphyseal growth plates of the long bones (1). It acts mainly on the resting zone chondrocytes and is responsible for local insulin-like growth factor (IGF)-I production, which stimulates clonal expansion of proliferating chondrocytes in an autocrine/paracrine manner (2). GH stimulates bone growth in length and diameter, enhancing the accrual of trabecular (3) and cortical bone (4) up to the attainment of peak bone mass in young adulthood (5).

We have previously shown that final height in GH-deficient (GHD) patients is dosage dependent (6). We therefore wondered whether a different GH dosage could also influence the geometry of the long bones. In fact, both GH and IGF-I stimulate the cortical bone directly (7, 8), as well as indirectly, by increasing the muscle strength and thus the bone load (9, 10). The aim of this study was thus to verify whether a different GH dosage, in addition to its effect on final height, would also influence the bone geometry and the bone strength of the metacarpal bone in two groups of GHD children.

Subjects and methods

Seventy-five children (48M, 27F) with isolated idiopathic GH deficiency were selected for the study. The diagnosis of GH deficiency was based on the following criteria: height of < 2 SDS and/or height velocity of < 10th centile for chronologic age when measured for more than 6 months; bone age delay of > 2 years compared with chronologic age and GH peak of < 10 µg/l after at least two consecutive conventional pharmacologic tests. All children had a normal hypophysis on magnetic resonance imaging (MRI), and were not affected by any cardiovascular, respiratory, renal or rheumatic diseases, or by any other endocrine disorders.

Thirty-eight children (25M, 13F) were treated in Pavia with a weekly recombinant GH dosage of 0.16 mg/kg for
a mean period of 4.9±2.5 years (group 1), while the other 37 (23 M, 14 F) were treated in Bolzano with a weekly recombinant GH dosage of 0.3 mg/kg for a mean period of 3.9±1.5 years (group 2). The auxologic features of the patients are reported in Table 1. They were all regularly followed up every 6 months until final height. GH treatment was discontinued at a bone age of >15 years in girls and >17 years in boys. Height was measured in both centers with a wall-mounted Harpenden stadiometer by the same trained personnel and reported as height SDS for chronologic age according to Tanner and Whitehouse (11). Moreover, in order to compare also the patient’s genetic potential for growth, we calculated the parentally adjusted height SDS, that is, the difference between height SDS for chronologic age and target height SDS (average height of both parents plus 6.55 cm for boys and minus 6.55 cm for girls). The difference between the parentally adjusted height SDS on attainment of adult stature and that before starting treatment was defined as relative height gain. The body-mass index (weight (kg)/height2 (m2)) was measured in both centers with a wall-mounted Harpenden stadiometer by the same trained personnel and reported as BMI SDS.

**Statistical analysis**

The data were normally distributed and are reported as mean±S.D. Student’s paired and unpaired *t*-tests were used to verify differences within and between groups. One-way analysis of variance (ANOVA) was also used to check differences in the MI between GHD, obese and tall children. A *P* value of less than 0.05 was considered statistically significant. The statistical program Statgraphics V5.1 (Magnugistics, Rockville, MD, USA) was employed.

**Results**

**Auxology**

Before treatment, group 1 showed a greater height SDS (Table 1) (*P* < 0.0001) and parentally adjusted height SDS than group 2 (Table 2) (*P* < 0.0001). However, at the end of treatment, at a mean age of 15.8±1.6 and 16.9±1.7 years respectively, no difference in height SDS (Table 1) and parentally adjusted height SDS (Table 2) was seen. The catch-up growth in group 2 is well accounted for by the relative greater height gain observed in this group (Table 2) (*P* < 0.0001). BMI SDS was similar in the two groups at final height (0.35±1.2 vs 0.63±1.53).

**Bone geometry**

MI SDS was greater in group 1 before treatment (*P* < 0.05) as well as at final height (Table 3) (*P* < 0.005). There was, however, no difference in the

<table>
<thead>
<tr>
<th>Table 1 Baseline and final characteristics of the 75 GHD children.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>No. of subjects</td>
</tr>
<tr>
<td>Chronologic age (years)</td>
</tr>
<tr>
<td>Bone age (years)</td>
</tr>
<tr>
<td>Height SDS</td>
</tr>
<tr>
<td>BMI SDS</td>
</tr>
<tr>
<td>TH</td>
</tr>
<tr>
<td>FH SDS</td>
</tr>
</tbody>
</table>

TH: target height; FH: final height.

*P < 0.05.

<table>
<thead>
<tr>
<th>Table 2 Parentally adjusted height SDS and relative height gains.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Group 1</td>
</tr>
<tr>
<td>Group 2</td>
</tr>
</tbody>
</table>

*P < 0.001.

<table>
<thead>
<tr>
<th>Table 3 Metacarpal index SDS at baseline and at final height.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Group 1</td>
</tr>
<tr>
<td>Group 2</td>
</tr>
</tbody>
</table>

*P < 0.05; **P < 0.005.
relative gain between the two groups, suggesting no dosage effect of GH. No difference was found when MI SDS was compared with those of the groups of tall and obese children (Fig. 1).

Outer and inner diameters were similar in the two groups at baseline and at final height (Table 4). Total, cortical and medullary CSA were also similar at baseline, while, at final height, the medullary CSA area was significantly larger in group 2. The percentage changes from baseline to final height (group 1 vs group 2) were as follows: 46.8% vs 70.9% (total CSA; NS), 10% vs 119% (medullary CSA; P = 0.002) and 61.7 vs 68.4% (cortical CSA; NS).

Bone strength

BBRI was similar in the two groups at the beginning and at the end of the study; however, BBRI increased significantly more in group 2 than in group 1 (P < 0.05). The percentage changes from baseline to final height (group 1 vs group 2) were 91% vs 138% (NS).

Discussion

The major finding of this study is that higher doses of GH significantly improve adult stature in GHD children, by stimulating better bone growth in length and diameter and by inducing minor but advantageous changes in bone geometry. The greater height gain by the children receiving the higher GH dosage agrees with our previous experience in a smaller group of children (6), emphasizing once again the appropriateness of the dosage of 0.3 mg/kg per week, as also recently recommended by the GH Research Society (16). Children grow because their bones become progressively longer and larger, a process which is under the influence of genetic, environmental and nutritional factors, as well as hormones, such as thyroid hormones, sex hormones, cortisol, GH and IGF-I. Thus, we wished to determine whether a higher dose of GH, besides making the bone grow faster, would also influence its geometry and therefore its resistance to fracture. Moreover, GH and IGF-I influence not only the bone growth but also its mineralization. Evaluation of bone mineral density by bone densitometry (DXA), a technique not comparable with the one used in our study, showed a lower degree of mineralization in GHD children, which normalized after treatment (17, 18) and a higher degree of mineralization in acromegaly (19, 20). Furthermore, local overexpression of IGF-I has been shown to increase trabecular bone formation and osteoblastic cell proliferation in unloaded rats (21). At the higher doses employed in this study, however, GH seems to have mainly a permissive role in mineralization, since in a previous study we could not find any difference in the bone mineral density of the radius and of the metacarpal bone in two groups of GHD children similarly treated (22).

In this study, cortical thickness was lower in the group treated with the higher dosage before starting treatment with GH and at final height as well (Table 2). Since no statistical difference in the relative MI SDS gain (Table 3) was observed, we feel that differences in MI SDS between groups might be explained entirely on a genetic basis without GH interference.

Nevertheless, we observed some differences, although not all statistically significant, in bone geometry between the two groups which could be attributed to the GH action. In fact, the children treated with higher doses tended to have larger bones at final height, as shown by the greater outer diameter and greater total CSA. Of interest is also the fact that they showed a similar cortical CSA to the other group, together with a significant enlargement of the medullary CSA (P < 0.05), indicating that the bone in these children was further placed from the neutral axis. This is a favorable situation since the periosteal apposition confers more strength in bending than bone deposited by endocortical apposition nearer to the

Table 4 Outer (D) and inner (d) diameter and total CSA, medullary CSA and cortical CSA and BBRI at baseline (B) and at final height (f).

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>D (cm)</th>
<th>d (cm)</th>
<th>Total CSA (cm²)</th>
<th>Medullary CSA (cm²)</th>
<th>Cortical CSA (cm²)</th>
<th>BBRI (cm³)</th>
<th>BBRI gain (cm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 (f)</td>
<td>38</td>
<td>8.45±1.52</td>
<td>4.06±0.56</td>
<td>57.82±21.97</td>
<td>13.18±3.88</td>
<td>44.63±20.32</td>
<td>6.64±3.98</td>
<td></td>
</tr>
<tr>
<td>Group 1 (l)</td>
<td>38</td>
<td>9.93±1.44</td>
<td>4.19±0.9</td>
<td>78.92±24.8</td>
<td>14.45±6.03</td>
<td>64.46±23.74</td>
<td>10.02±5.37</td>
<td>3.33±5.06</td>
</tr>
<tr>
<td>Group 2 (b)</td>
<td>37</td>
<td>8.51±1.85</td>
<td>4.0±1.05</td>
<td>59.5±29.66</td>
<td>13.44±6.38</td>
<td>46.07±26.95</td>
<td>5.79±3.26</td>
<td></td>
</tr>
<tr>
<td>Group 2 (f)</td>
<td>37</td>
<td>10.12±1.76</td>
<td>4.65±1.6</td>
<td>82.69±27.26</td>
<td>18.94±12.36*</td>
<td>63.75±23.4</td>
<td>11.52±5.49</td>
<td>6.88±6.65*</td>
</tr>
</tbody>
</table>

CSA: cross-sectional area.

*P < 0.05 for the difference between group 1 (f) and Group 2 (f).
neutral axis of the long bone (23). We confirmed this beneficial effect of higher GH doses by finding a statistically significant increase in bone strength (BBRI) in this group compared with the other one. Similar findings have been recently reported in a group of children affected with juvenile idiopathic arthritis and treated with GH for a similar period of time (24). Apart from GH, gender differences within the two groups could have played a role in modulating the changes in bone geometry, since it is known that testosterone mainly stimulates periosteal apposition, while estrogen inhibits periosteal bone apposition and stimulates endocortical bone formation (25). Boys and girls, however, were equally represented in the two groups, and thus gender differences are unlikely to play a role.

In conclusion, higher doses of GH, apart from their effect on adult stature, seem to exert also a positive effect on bone geometry, which would lead to an improved bone stability and thus increased resistance to fractures. However, further studies are needed to confirm the beneficial effect of higher GH doses on adult stature and bone strength.

References